Literature DB >> 19048267

False negative result for amphetamines on the Triage Drug of Abuse panel? The cause of the unusual phenomenon with experimental analyses.

Wakako Hikiji1, Keiko Kudo, Shinji Sato, Yosuke Usumoto, Akiko Tsuji, Noriaki Ikeda.   

Abstract

On-site drug screening devices are widely used today for their simple test procedures and instantaneous results. Among other devices, a Triage Drug of Abuse panel is considered to be highly reliable for its high specificity and sensitivity of abused drugs. Although it is known that a false positive amphetamine (AMP) result may be obtained from the urine samples containing putrefactive amines or ephedrine-related compounds, no clinical false negative methamphetamine results have been reported to date. However, a false negative Triage result was obtained from the urine of a fatal methamphetamine poisoning victim taking Vegetamine tablets. Further experimental analyses revealed that the cross-reactivity of methamphetamine and chlorpromazine metabolites, including nor-2-chlorpromazine sulfoxide, was the cause for a false negative Triage reaction for AMP. Forensic scientists and clinicians must be aware of the limitations of on-site drug testing devices and the need for the confirmatory laboratory tests for the precise identification and quantification of drugs in suspicious intoxication cases, as also recommended by the manufacturers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19048267     DOI: 10.1007/s00414-008-0304-9

Source DB:  PubMed          Journal:  Int J Legal Med        ISSN: 0937-9827            Impact factor:   2.686


  19 in total

Review 1.  Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics.

Authors:  M Schulz; A Schmoldt
Journal:  Pharmazie       Date:  2003-07       Impact factor: 1.267

2.  Metabolites of chlorpromazine and brompheniramine may cause false-positive urine amphetamine results with monoclonal EMIT d.a.u. immunoassay.

Authors:  K M Olsen; M Gulliksen; A S Christophersen
Journal:  Clin Chem       Date:  1992-04       Impact factor: 8.327

3.  Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon?

Authors:  M Pavlic; K Libiseller; P Grubwieser; W Rabl
Journal:  Int J Legal Med       Date:  2005-04-16       Impact factor: 2.686

4.  Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles.

Authors:  S B Karch; B G Stephens; C H Ho
Journal:  J Forensic Sci       Date:  1999-03       Impact factor: 1.832

5.  Reduced interference by phenothiazines in amphetamine drug of abuse immunoassays.

Authors:  Stacy E F Melanson; Elizabeth Lee-Lewandrowski; David A Griggs; William H Long; James G Flood
Journal:  Arch Pathol Lab Med       Date:  2006-12       Impact factor: 5.534

6.  False-positive results with Emit II amphetamine/methamphetamine assay in users of common psychotropic drugs.

Authors:  A Smith-Kielland; K M Olsen; A S Christophersen
Journal:  Clin Chem       Date:  1995-06       Impact factor: 8.327

7.  A field evaluation of five on-site drug-testing devices.

Authors:  Dennis J Crouch; Rebekah K Hersch; Royer F Cook; James F Frank; J Michael Walsh
Journal:  J Anal Toxicol       Date:  2002-10       Impact factor: 3.367

8.  Performance evaluation of four on-site drug-testing devices for detection of drugs of abuse in urine.

Authors:  M R Peace; L D Tarnai; A Poklis
Journal:  J Anal Toxicol       Date:  2000-10       Impact factor: 3.367

9.  Crystal methamphetamine-associated cardiomyopathy: tip of the iceberg?

Authors:  Mevan Wijetunga; Todd Seto; Joseph Lindsay; Irwin Schatz
Journal:  J Toxicol Clin Toxicol       Date:  2003

10.  Cardiomyopathy associated with the smoking of crystal methamphetamine.

Authors:  R Hong; E Matsuyama; K Nur
Journal:  JAMA       Date:  1991-03-06       Impact factor: 56.272

View more
  1 in total

1.  Triage DOA® versus INSTANT-VIEW M-1® in Urinary Drug Screening for Acute Drug Poisoning: A Prospective Cross-sectional Study.

Authors:  Aoi Fujikawa; Sachiko Ohde; Norio Otani; Shinichi Ishimatsu
Journal:  Intern Med       Date:  2019-09-15       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.